EA009781B1 - Фармацевтическая композиция и ее применение для лечения нарушений функции мочевого пузыря - Google Patents

Фармацевтическая композиция и ее применение для лечения нарушений функции мочевого пузыря Download PDF

Info

Publication number
EA009781B1
EA009781B1 EA200500776A EA200500776A EA009781B1 EA 009781 B1 EA009781 B1 EA 009781B1 EA 200500776 A EA200500776 A EA 200500776A EA 200500776 A EA200500776 A EA 200500776A EA 009781 B1 EA009781 B1 EA 009781B1
Authority
EA
Eurasian Patent Office
Prior art keywords
ethyl
bladder
hydroxy
amino
incontinence
Prior art date
Application number
EA200500776A
Other languages
English (en)
Russian (ru)
Other versions
EA200500776A1 (ru
Inventor
Людвиг Мельбургер
Мартин Михель
Марион Винрих
Урсула Эбингер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA200500776A1 publication Critical patent/EA200500776A1/ru
Publication of EA009781B1 publication Critical patent/EA009781B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
EA200500776A 2002-11-27 2003-11-03 Фармацевтическая композиция и ее применение для лечения нарушений функции мочевого пузыря EA009781B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026546A EP1424079A1 (en) 2002-11-27 2002-11-27 Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PCT/EP2003/012225 WO2004047830A2 (de) 2002-11-27 2003-11-03 Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen

Publications (2)

Publication Number Publication Date
EA200500776A1 EA200500776A1 (ru) 2005-12-29
EA009781B1 true EA009781B1 (ru) 2008-04-28

Family

ID=32241298

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500776A EA009781B1 (ru) 2002-11-27 2003-11-03 Фармацевтическая композиция и ее применение для лечения нарушений функции мочевого пузыря

Country Status (22)

Country Link
US (2) US20090012161A9 (enExample)
EP (4) EP1424079A1 (enExample)
JP (2) JP2006509751A (enExample)
KR (1) KR20050088295A (enExample)
CN (1) CN1717230A (enExample)
AT (1) ATE399005T1 (enExample)
AU (2) AU2003285312A1 (enExample)
BR (1) BR0316535A (enExample)
CA (2) CA2507266A1 (enExample)
CO (1) CO5580754A2 (enExample)
DE (1) DE50310046D1 (enExample)
EA (1) EA009781B1 (enExample)
EC (1) ECSP055814A (enExample)
ES (1) ES2309371T3 (enExample)
HR (1) HRP20050467A2 (enExample)
MX (1) MXPA05005483A (enExample)
NO (1) NO20053088L (enExample)
PL (1) PL376259A1 (enExample)
RS (1) RS20050392A (enExample)
UA (1) UA81931C2 (enExample)
WO (2) WO2004047830A2 (enExample)
ZA (1) ZA200503282B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2670749C2 (ru) * 2012-09-18 2018-10-25 ТАРИС Биомедикал ЛЛК Системы доставки лекарственного средства и способы лечения дисфункции опорожнения мочевого пузыря и других расстройств нижних мочевыводящих путей с использованием троспия

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
KR20060124603A (ko) * 2003-11-03 2006-12-05 베링거 인겔하임 인터내셔날 게엠베하 베타-3-아드레날린 수용체 효능제 및 알파 길항제 및/또는5-알파-리덕타제 억제제를 함유하는 약제학적 조성물
DE10356112A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
EP1804778A1 (de) * 2004-10-18 2007-07-11 Boehringer Ingelheim International GmbH Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
US20090247781A1 (en) * 2004-10-26 2009-10-01 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
US20090131469A1 (en) * 2005-02-25 2009-05-21 Astellas Pharma Inc. Pharmaceutical agent comprising solifenacin
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
US9440003B2 (en) * 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
US20100172988A1 (en) * 2006-01-10 2010-07-08 Kissei Pharmaceutical Co., Ltd. Sustained release preparation and method for production thereof
US20070292511A1 (en) * 2006-05-22 2007-12-20 Gershon Kolatkar Duloxetine hydrochloride delayed release formulations
US20090175935A1 (en) * 2006-08-14 2009-07-09 Torrent Research Ltd. Pharmaceutical compositions of duloxetine
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
PT2216021E (pt) 2007-11-02 2012-11-06 Astellas Pharma Inc Composição farmacêutica para tratar uma bexiga hiperactiva
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
ES2376095B1 (es) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. Pellets entéricos de duloxetina.
WO2010053068A1 (ja) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
EP2316432A1 (de) * 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2377525A1 (en) * 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
KR20180008918A (ko) * 2010-08-03 2018-01-24 앨씨알엑스, 인크. 과민성 방광 치료를 위한 베타-3 아드레날린 수용체 작용제 및 무스카린 수용체 길항제의 약학적 배합제
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
KR20150020160A (ko) * 2012-02-09 2015-02-25 앨씨알엑스, 인크. 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
JP2018536453A (ja) * 2015-10-15 2018-12-13 デューク ユニバーシティ 膀胱機能障害を処置するための状態依存的末梢神経調節
WO2017070689A2 (en) 2015-10-23 2017-04-27 Velicept Therapeutics, Inc. Solabegron zwitterion and uses thereof
WO2017186598A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Modified release tablet composition comprising mirabegron
US20190307696A1 (en) 2016-04-25 2019-10-10 Synthon B.V. Tablets comprising mirabegron and solifenacin
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0654264A1 (en) * 1993-11-24 1995-05-24 Eli Lilly And Company Treatment of incontinence with venlafaxine or an aryloxy propanamine compound
US5441985A (en) * 1991-02-25 1995-08-15 Eli Lilly And Company Treatment of lower urinary tract disorders with selective norepinephrine uptake inhibitors
WO1997033880A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
EP0958835A1 (en) * 1996-08-19 1999-11-24 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
WO2000002846A1 (fr) * 1998-07-08 2000-01-20 Kissei Pharmaceutical Co., Ltd. Derives d'acide phenoxyacetique et compositions medicinales contenant lesdits derives
EP1043308A1 (en) * 1997-12-18 2000-10-11 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
EP1072583A1 (en) * 1998-04-14 2001-01-31 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2002053140A2 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20020128247A1 (en) * 2001-03-01 2002-09-12 Dow Robert L. Beta3 agonists and uses thereof
WO2002085871A2 (en) * 2001-04-04 2002-10-31 Wyeth Serotonergic agents with long-acting in vivo effects
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
AU715216B2 (en) * 1995-10-26 2000-01-20 Mitsubishi-Tokyo Pharmaceuticals, Inc. Phenylethanolamine compounds useful as beta3 agonist, process for producing the same, and intermediates in the production of the same
CA2242351C (en) * 1996-01-10 2003-03-11 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
WO1998003067A1 (en) * 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
WO1998021184A1 (en) * 1996-11-14 1998-05-22 Pfizer Inc. Process for substituted pyridines
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
JPH1112171A (ja) * 1997-06-19 1999-01-19 Nisshin Flour Milling Co Ltd 消化器疾患治療薬
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
DK1028111T3 (da) * 1997-10-17 2004-09-20 Yamanouchi Pharma Co Ltd Amidderivater eller salte heraf
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
WO1999051564A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
SI1039882T1 (sl) * 1998-08-27 2011-01-31 Pfizer Health Ab Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
EP1078924B1 (en) * 1999-07-23 2004-10-20 Pfizer Products Inc. Intermediates and a process for producing beta-adrenergic receptor agonists
PT1227806E (pt) * 1999-11-11 2005-10-31 Pfizer Health Ab Formulacao farmaceutica contendo tolterodina e sua utilizacao
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
DE60045082D1 (de) * 2000-06-07 2010-11-18 Watson Pharmaceuticals Inc Behandlung von überaktivität glatter muskulatur mit (r)-oxybutynin und (r)-desethyloxybutynin
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
WO2003035600A1 (en) * 2001-10-19 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Process for producing benzocycloheptene derivative
US20030144352A1 (en) * 2001-11-05 2003-07-31 Cammarata Sue K. Antimuscarinic aerosol
JP2005526040A (ja) * 2002-02-19 2005-09-02 ファルマシア・コーポレーション 失禁の治療のためのシクロオキシゲナーゼ阻害剤及び抗ムスカリン剤の使用

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441985A (en) * 1991-02-25 1995-08-15 Eli Lilly And Company Treatment of lower urinary tract disorders with selective norepinephrine uptake inhibitors
EP0654264A1 (en) * 1993-11-24 1995-05-24 Eli Lilly And Company Treatment of incontinence with venlafaxine or an aryloxy propanamine compound
WO1997033880A1 (en) * 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
EP0958835A1 (en) * 1996-08-19 1999-11-24 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
EP1043308A1 (en) * 1997-12-18 2000-10-11 Kissei Pharmaceutical Co., Ltd. Phenylaminoalkylcarboxylic acid derivatives and medicinal compositions containing the same
EP1072583A1 (en) * 1998-04-14 2001-01-31 Kissei Pharmaceutical Co., Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
WO2000002846A1 (fr) * 1998-07-08 2000-01-20 Kissei Pharmaceutical Co., Ltd. Derives d'acide phenoxyacetique et compositions medicinales contenant lesdits derives
EP1095932A1 (en) * 1998-07-08 2001-05-02 Kissei Pharmaceutical Co., Ltd. Phenoxyacetic acid derivatives and medicinal compositions containing the same
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
US20020010216A1 (en) * 2000-02-24 2002-01-24 Karen Rogosky New drug combinations
WO2002053140A2 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US20020128247A1 (en) * 2001-03-01 2002-09-12 Dow Robert L. Beta3 agonists and uses thereof
WO2002085871A2 (en) * 2001-04-04 2002-10-31 Wyeth Serotonergic agents with long-acting in vivo effects

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANDERSSON K.-E.: "THE OVERACTIVE BLADDER: PHARMACOLOGIC BASIS OF DRUG TREATMENT", UROLOGY, BELLE MEAD, NJ, US, vol. 50, no. 6, SUPPL 1, 1997, pages 74-84, XP001189072, ISSN: 0090-4295, page 78, right-hand column, last paragraph - page 79, left-hand column, paragraph 3 *
SALETU B. ET AL.: "TANDAMINE - A NEW NOREPINEPHRINE REUPTAKE INHIBITOR CLINICAL, PSYCHOMETRIC AND QUANTITATIVE EEG STUDIES IN DEPRESSED PATIENTS", INTERNATIONAL PHARMACOPSYCHIATRY, KARGER, BASEL, CH, vol. 12, no. 3, 1977, pages 137-152, XP000605654, ISSN: 0020-8272, abstract *
SELLERS DONNA J. ET AL.: "Potential therapeutic targets for treatment of the overactive bladder", WORLD JOURNAL OF UROLOGY, SPRINGER INTERNATIONAL, DE, vol. 19, no. 5, 2001, pages 307-311, XP002971377, ISSN: 0724-4983, page 307, right-hand column, paragraph 2 - page 308, left-hand column, paragraph 2 *
SHARMA A. ET AL.: "PHARMACOKINETICS AND SAFETY OF DULOXETINE, A DUAL-SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR", JOURNAL OF CLINICAL PHARMACOLOGY, LIPPINCOTT CO, HAGERSTOWN, MD, US, vol. 40, no. 2, February 2000 (2000-02), pages 161-167, XP000904872, ISSN: 0091-2700, abstract, page 161, paragraph 1 - paragraph 2 *
SPRINGER J. P. ET AL.: "FACILITATORY AND INHIBITORY EFFECTS OF SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS ON HYPOGASTRIC NERVE-EVOKED URETHRAL CONTRACTIONS IN THE CAT: A PROMINENT ROLE OF URETHRAL BETA-ADRENERGIC RECEPTORS", JOURNAL OF UROLOGY, BALTIMORE, MD, US, vol. 152, no. 2, PART 1, August 1994 (1994-08), pages 515-519, XP008020464, ISSN: 0022-5347, abstract, page 515, left-hand column, paragraph 1 - paragraph 2, page 517, right-hand column, last paragraph - page 519, left-hand column, paragraph 1 *
THOR K. B. ET AL.: "EFFECTS OF DULOXETINE, A COMBINED SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR, ON CENTRAL NEURON CONTROL OF LOWER URINARY TRACT FUNCTION IN THE CHLORALOSE-ANESTHETIZED FEMAL CAT", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 274, no. 2, 1995, pages 1014-1024, XP009023623, ISSN: 0022-3565, abstract *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2670749C2 (ru) * 2012-09-18 2018-10-25 ТАРИС Биомедикал ЛЛК Системы доставки лекарственного средства и способы лечения дисфункции опорожнения мочевого пузыря и других расстройств нижних мочевыводящих путей с использованием троспия
RU2670749C9 (ru) * 2012-09-18 2018-12-13 ТАРИС Биомедикал ЛЛК Системы доставки лекарственного средства и способы лечения дисфункции опорожнения мочевого пузыря и других расстройств нижних мочевыводящих путей с использованием троспия

Also Published As

Publication number Publication date
CA2507266A1 (en) 2004-06-10
ZA200503282B (en) 2006-07-26
WO2004047830A3 (de) 2004-08-19
KR20050088295A (ko) 2005-09-05
WO2004047838A3 (de) 2004-10-28
CN1717230A (zh) 2006-01-04
ATE399005T1 (de) 2008-07-15
CO5580754A2 (es) 2005-11-30
JP2006509751A (ja) 2006-03-23
UA81931C2 (uk) 2008-02-25
EP1424079A1 (en) 2004-06-02
BR0316535A (pt) 2005-10-04
RS20050392A (sr) 2007-04-10
MXPA05005483A (es) 2005-08-16
DE50310046D1 (de) 2008-08-07
ECSP055814A (es) 2005-08-11
AU2003289854A1 (en) 2004-06-18
EP1640000A3 (de) 2007-01-17
EP1640000A2 (de) 2006-03-29
WO2004047838A2 (de) 2004-06-10
JP2006509752A (ja) 2006-03-23
ES2309371T3 (es) 2008-12-16
US20050261369A1 (en) 2005-11-24
HRP20050467A2 (en) 2006-06-30
EP1572181B1 (de) 2008-06-25
EP1572181A2 (de) 2005-09-14
NO20053088L (no) 2005-06-23
US20050261328A1 (en) 2005-11-24
PL376259A1 (pl) 2005-12-27
US20090012161A9 (en) 2009-01-08
EA200500776A1 (ru) 2005-12-29
AU2003285312A1 (en) 2004-06-18
WO2004047830A2 (de) 2004-06-10
CA2507343A1 (en) 2005-07-14
EP1567149A2 (de) 2005-08-31

Similar Documents

Publication Publication Date Title
EA009781B1 (ru) Фармацевтическая композиция и ее применение для лечения нарушений функции мочевого пузыря
US20050119239A1 (en) Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and an active substance which influences prostaglandin metabolism
AU748993B2 (en) Pharmaceutical combinations containing tramadol
US20050101607A1 (en) Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor
CA2442410A1 (en) Duloxetine for treatment of hot flashes
US20050154041A1 (en) Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist
WO2003026564A9 (en) Pharmaceutical compositions for the treatment of urinary disorders
ZA200402362B (en) Pharmaceutical compositions for the treatment of urinary disorders.
WO2005067925A1 (en) Derivatives of aryl(or heteroaryl) azolylcarbinols for the treatment of enuresis
US6150396A (en) Methods of treating or preventing interstitial cystitis
US20070129435A1 (en) Pharmaceutical Composition For Treating Stress Incontinence And/Or Mixed Incontinence
AU2003287499A1 (en) Treatment of gastrointestinal disorders with duloxetine
HK1035143B (en) Pharmaceutical combinations containing tramadol for the production of a medicament for the treatment of migraine or migrainoid headaches
AU2002341479A1 (en) Pharmaceutical compositions for the treatment of urinary disorders

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU